JPRN-UMIN000048457
Not yet recruiting
未知
A multi center, phase 3 study to evaluate safety and efficacy of extensive intraoperative peritoneal lavage, that project to prevent recurrence, in the laparoscopic surgery for advanced colon cancer - SENJYO study
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group0 sites2,600 target enrollmentJuly 26, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
- Enrollment
- 2600
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with history of surgery within 4weeks 2\) Patients with multiple cancers
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
A multi center, phase 2 study to Evaluate safety and efficacy of total Neoadjuvant treatment of long courSE radiotherapy followed by cheMotherapy, capecitaBine combined with oxaliplatin (CAPOX) for Locally advanced rEctal cancer(ENSEMBLE-2)JPRN-jRCTs071210143KAGAWA Yoshinori27
Active, not recruiting
Phase 1
A Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-002108-41-ITMitsubishi Tanabe Development America Inc.185
Active, not recruiting
Phase 1
A Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-002108-41-DEMitsubishi Tanabe Pharma Development America, Inc.185
Active, not recruiting
Not Applicable
A multicenter study of the safety and efficacy of adalimumab in subjectswith moderate to severe hidradenitis suppurativaHidradenitis SupperativaMedDRA version: 14.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2011-003406-24-DKAbbVie Deutschland GmbH & Co. KG300
Active, not recruiting
Not Applicable
A multicenter study of the safety and efficacy of adalimumab in subjectswith moderate to severe hidradenitis suppurativaHidradenitis SupperativaMedDRA version: 14.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2011-003406-24-NLAbbVie Deutschland GmbH & Co. KG300